PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.81%
EBIT growth below 50% of TRAW's 100.00%. Michael Burry would suspect deeper competitive or cost structure issues.
36.41%
Positive operating income growth while TRAW is negative. John Neff might view this as a competitive edge in operations.
439.57%
Positive net income growth while TRAW is negative. John Neff might see a big relative performance advantage.
440.81%
Positive EPS growth while TRAW is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
440.81%
Positive diluted EPS growth while TRAW is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
681.03%
Positive OCF growth while TRAW is negative. John Neff would see this as a clear operational advantage vs. the competitor.
681.03%
Positive FCF growth while TRAW is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1209.68%
10Y OCF/share CAGR above 1.5x TRAW's 77.68%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
1209.68%
Positive OCF/share growth while TRAW is negative. John Neff might see a comparative advantage in operational cash viability.
1209.68%
Positive 3Y OCF/share CAGR while TRAW is negative. John Neff might see a big short-term edge in operational efficiency.
934.70%
Net income/share CAGR above 1.5x TRAW's 98.31% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
934.70%
Positive 5Y CAGR while TRAW is negative. John Neff might view this as a strong mid-term relative advantage.
934.70%
Positive short-term CAGR while TRAW is negative. John Neff would see a clear advantage in near-term profit trajectory.
-244.00%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-244.00%
Negative 5Y equity/share growth while TRAW is at 10162.80%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-244.00%
Negative 3Y equity/share growth while TRAW is at 7609.85%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2826.88%
Asset growth well under 50% of TRAW's 81849.33%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
26.94%
Under 50% of TRAW's 59775.48%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
3.22%
Debt growth of 3.22% while TRAW is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
No Data
No Data available this quarter, please select a different quarter.
-10.82%
We cut SG&A while TRAW invests at 61301.60%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.